ProCE Banner Activity

How I Treat My Patients With CLL Who Are Fit or Otherwise Healthy

Clinical Thought
Chemotherapy or novel agents for initial treatment of CLL? Learn how to best apply new molecular markers to individualize treatment for your patients who are fit or otherwise healthy.

Released: March 11, 2015

Expiration: March 09, 2016

No longer available for credit.

Share

Faculty

Jeffrey P. DONOTUSESharman

Jeffrey P. DONOTUSESharman, MD

Medical Oncologist
Willamette Valley Cancer Institute and Research Center
Springfield, Oregon

Jeff DONOTUSESharman

Jeff DONOTUSESharman, MD

Medical Director of Hematology Research
Willamette Valley Cancer Institute
US Oncology
Eugene, Oregon

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Novartis Oncology

Faculty Disclosure

Primary Author

Jeffrey P. DONOTUSESharman, MD

Medical Oncologist
Willamette Valley Cancer Institute and Research Center
Springfield, Oregon

Jeff P. Sharman, MD, has disclosed that he has received consulting fees and funds for research support from Acerta, Celgene, Genentech, Gilead Sciences, Pharmacyclics, Seattle Genetics, and TG Therapeutics.

Jeff DONOTUSESharman, MD

Medical Director of Hematology Research
Willamette Valley Cancer Institute
US Oncology
Eugene, Oregon

Jeff P. Sharman, MD, has disclosed that he has received consulting fees and funds for research support from Acerta, Celgene, Genentech, Gilead Sciences, Pharmacyclics, Seattle Genetics, and TG Therapeutics.